• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]".

作者信息

Piccirillo Maria Carmela, Chu Quincy, Bradbury Penelope, Tu Wei, Coschi Courtney H, Grosso Federica, Florescu Marie, Mencoboni Manlio, Goffin John R, Pagano Maria, Ciardiello Fortunato, Cecere Fabiana Letizia, Vincent Mark, Ferrara Roberto, Dawe David E, Hao Desiree, Lee Christopher W, Morabito Alessandro, Gridelli Cesare, Cavanna Luigi, Iqbal Mussawar, Blais Normand, Leighl Natasha B, Wheatley-Price Paul, Tsao Ming-Sound, Ugo Francesca, El-Osta Hazem, Gargiulo Piera, Gaudreau Pierre-Olivier, Tu Dongsheng, Sederias Joana, Brown-Walker Pamela, Perrone Francesco, Seymour Lesley, Laurie Scott A

机构信息

Clinical Trials Unit, Istituto Nazionalei Tumori Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione G. Pascale, Napoli, Italy.

Cross Cancer Institute, Edmonton, Alberta, Canada.

出版信息

J Thorac Oncol. 2024 Nov;19(11):1578-1579. doi: 10.1016/j.jtho.2024.08.017. Epub 2024 Aug 24.

DOI:10.1016/j.jtho.2024.08.017
PMID:39186030
Abstract
摘要

相似文献

1
Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]".《“简要报告：加拿大癌症试验组IND.227：帕博利珠单抗治疗晚期恶性胸膜间皮瘤患者的II期随机研究（NCT02784171）”勘误》。[《胸部肿瘤学杂志》第18卷第6期：813 - 819页]
J Thorac Oncol. 2024 Nov;19(11):1578-1579. doi: 10.1016/j.jtho.2024.08.017. Epub 2024 Aug 24.
2
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).简要报告：加拿大癌症临床试验组 IND.227：一项评估派姆单抗治疗晚期恶性胸膜间皮瘤的 2 期随机研究（NCT02784171）。
J Thorac Oncol. 2023 Jun;18(6):813-819. doi: 10.1016/j.jtho.2023.02.003. Epub 2023 Feb 24.
3
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.帕博利珠单抗联合化疗对比单纯化疗用于未经治疗的加拿大、意大利和法国晚期胸膜间皮瘤的 3 期、开放标签、随机对照临床试验。
Lancet. 2023 Dec 16;402(10419):2295-2306. doi: 10.1016/S0140-6736(23)01613-6. Epub 2023 Nov 3.
4
"Brief Report: Canadian Cancer Trials Group IND.227": Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma.简短报告：加拿大癌症试验组IND.227：剖析单药帕博利珠单抗在晚期恶性胸膜间皮瘤中的临床潜力
J Thorac Oncol. 2023 Jun;18(6):e67-e68. doi: 10.1016/j.jtho.2023.03.009.
5
Response to a Letter Received Entitled: "'Brief Report: Canadian Cancer Trials Group IND.227': Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma".对一封来信的回复，信的标题为：“简要报告：加拿大癌症试验组IND.227”：剖析单药帕博利珠单抗在晚期恶性胸膜间皮瘤中的临床潜力
J Thorac Oncol. 2023 Jun;18(6):e68-e69. doi: 10.1016/j.jtho.2023.03.003.
6
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.帕博利珠单抗治疗恶性胸膜间皮瘤患者的临床安全性和疗效（KEYNOTE-028）：一项非随机、开放标签、Ib 期试验的初步结果。
Lancet Oncol. 2017 May;18(5):623-630. doi: 10.1016/S1470-2045(17)30169-9. Epub 2017 Mar 11.
7
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.一项比较派姆单抗与单药化疗治疗晚期预处理恶性胸膜间皮瘤的多中心随机 III 期试验：欧洲胸部肿瘤平台（ETOP 9-15）PROMISE-meso 试验。
Ann Oncol. 2020 Dec;31(12):1734-1745. doi: 10.1016/j.annonc.2020.09.009. Epub 2020 Sep 22.
8
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.帕博利珠单抗联合仑伐替尼二线和三线治疗胸膜间皮瘤患者（PEMMELA）：一项单臂 2 期研究。
Lancet Oncol. 2023 Nov;24(11):1219-1228. doi: 10.1016/S1470-2045(23)00446-1. Epub 2023 Oct 13.
9
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma.一名恶性胸膜间皮瘤患者出现的帕博利珠单抗相关微小病变病。
BMC Cancer. 2016 Aug 19;16:656. doi: 10.1186/s12885-016-2718-y.
10
Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes.恶性胸膜间皮瘤患者的临床试验资格：新型疗法的应用和结果。
Clin Lung Cancer. 2020 Jul;21(4):378-383.e1. doi: 10.1016/j.cllc.2020.01.007. Epub 2020 Mar 7.